Serum proteome-lipidome integration reveals a mitochondrial-lipid remodeling axis in MASH-associated fibrosis
Background Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of steatotic liver disease in which fibrosis is the principal determinant of adverse clinical outcomes. However, the circulating molecular architecture that links metabolic injury to fibrotic remodeling remains incompletely defined. Methods Untargeted UHPLC-MS/MS lipidomics was performed in a biopsy-characterized cohort of 60 individuals (30 with MASH-associated fibrosis and 30 with non-alcoholic fatty liver NAFL). Serum data-independent acquisition proteomics was performed in a randomly selected, balanced 20-participant sub-cohort (10 MASH and 10 NAFL), and this sub-cohort was used for the integrated multi-omics analyses. Results This analysis identified extensive molecular remodeling in MASH, comprising 422 differentially expressed proteins and 240 altered lipid species. Proteomic enrichment highlighted broad suppression of oxidative phosphorylation, fatty acid degradation, and tricarboxylic acid cycle pathways, together with activation of extracellular matrix-receptor interaction and focal adhesion pathways. Lipidomic profiling revealed predominant remodeling of glycerophospholipids, including marked alterations in phosphatidylcholines, phosphatidylethanolamines, and cardiolipins. Network analysis identified a fibrosis-associated protein module centered on SMPD1, PSMB5, GPD1, and IFI16, whereas cross-omics integration linked LPCAT3 to phosphatidylcholine remodeling and NR1I3 to triglyceride-associated variation. External transcriptomic validation across independent GEO cohorts supported concordant expression patterns for key signatures, including SMPD1, LPCAT3, CD177, and TMOD1. Conclusions MASH-associated fibrosis was associated with a coordinated serum proteome-lipidome state characterized by omics signatures consistent with altered mitochondrial energy metabolism, glycerophospholipid remodeling, and extracellular matrix activation, and nominate candidate molecular signatures for future mechanistic and biomarker studies.
Authors
- Sheng Gao (ORCID: https://orcid.org/0009-0001-7926-5719)
- Manying Zhang (ORCID: https://orcid.org/0000-0002-8803-6707)
- JiaEn Yang
- Weili Li (ORCID: https://orcid.org/0000-0002-3917-1339)
- Shaodong Chen (ORCID: https://orcid.org/0000-0003-4727-5135)
- Qianguo Mao
- Xinyi Kwan (ORCID: https://orcid.org/0009-0008-7570-2767)
- Yaoyu Liu
- Chuncheng Wu
- Xiaoting Zheng
- Yong Wang
- Siyan Chen
- Huiqing Liang
- Yue Chen
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Fujian University of Traditional Chinese Medicine (CN)
- Beijing University of Chinese Medicine (CN)
- Xiamen University (CN)
- Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1186/s12967-026-09177-9
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province